The present study is testing in a combined design to types of drugs in patients with chronic
heart failure: 1) Hydralazine in combination with isosorbide dinitrate (BiDil) and 2)
Metformin hydrochloride. The study is double blind, placebo controlled.
1. The first hypothesis is that hydralazine in combination with isosorbide dinitrate can
reduce mortality and hospitalization with worsening heart failure.
2. The second hypothesis is that treatment of underlying insulin resistance/ type 2
diabetes with metformin in heart failure patients with moderately to severely reduced
LVEF can reduce mortality and cardiovascular hospitalizations. Among secondary endpoints
are reduction in new-onset diabetes in heart failure patients with insulin resistance
and diabetes risk profile and patient safety.
Phase:
Phase 4
Details
Lead Sponsor:
Henrik Wiggers
Collaborators:
Danish Council for Independent Research Danish Heart Foundation The Aase og Ejnar Danielsen Foundation The Danish Regions: Foundation for Medical Research The Novo Nordisk Foundation